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Abstract Candida bracarensis is an uncommon
Candida species found during an epidemiological
study of candidiasis performed in Braga, Portugal.
Initially, it was identified as C. glabrata, but recently
detailed analyses pointed out their differences. So,
little information is still available aboutC. bracarensis
virulence factors and antifungal susceptibilities.
Therefore, the main goal of this work is to evaluate
the ability of C. bracarensis to form biofilms, to
produce hydrolytic enzymes (proteases, phospholi-
pases and hemolysins), as well as its susceptibility to
amphotericin B and fluconazole. It was shown, for the
first time, that all C. bracarensis strains were able to
form biofilms and display proteinase and hemolytic
activities. Moreover, although planktonic cells pre-
sented antifungal susceptibility, amphotericin B and
fluconazole were unable to inhibit biofilm formation
and eradicate pre-formed biofilms. Due to the propen-
sity of C. bracarensis to display antifungal resistance
and virulence attributes, the control of these emerging
pathogens is recommended.
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Introduction
Among the several Candida species that cause human
infections, Candida albicans is recognized as the most
frequent and pathogenic [1, 2]. Nevertheless, some
authors [3, 4] have reported that there are other
important pathogenic members in the Candida group,
namely Candida tropicalis, Candida glabrata and
Candida parapsilosis [5]. With the advances in the
polymerase chain reaction (PCR)-based techniques,
previously unrecognized ‘‘cryptic’’ species have been
identified and added to the list of human pathogens [6].
Recently,Candida bracarensiswas identified as a new
Candida species under an epidemiological study of
candidiasis performed in Braga, Portugal [7]. Initially,
it was phenotypically confused with C. glabrata, but
later some studies showed differences between them
and justified the description of a new species [6, 7].
Candida species present several virulence factors,
such as ability to adhere to host tissues or medical
devices, biofilm formation, hydrolytic enzymes produc-
tion (e.g., proteases, phospholipases and hemolysins)
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and ability to filament [6]. Biofilm formation, which
includes cells adhered to a surface and embedded in an
extracellularmatrix, is dependent on the strain, substrate
properties and growth conditions [8]. Hydrolytic
enzymes are causative agents of host destruction, while
the filamentous structures have a relevant role in the
invasion of pathogen in the host tissue [5].
The high prevalence of Candida species in infec-
tions, namely in a biofilm lifestyle, is also a reflection
of their inherent high level of resistance to certain
antifungal drugs [5]. Moreover, this resistance started
to increase among Candida species in consequence of
the rise of invasive fungal infections caused by the
same microorganisms [9]. With this argument of
infections, antifungal agents are being used exces-
sively, thus contributing to the increase in resistant
species and the occurrence of mutations related to
resistance [10]. Besides being a problem for human
health, antifungal resistance also causes big economic
problems [11].
The true clinical relevance of the possible misiden-
tification of C. bracarensis as C. glabrata is under
evaluation, since this species is relatively rare [12].
However, in vitro susceptibility studies of C.
bracarensis isolates were comparable to those found
with C. glabrata [6, 12]. Thus, it is important to study
this emerging human pathogen. To author’s best
knowledge, to date, there are no in vitro studies for
the determination of C. bracarensis virulence factors
and only few concerning its antifungal resistance [6,
12]. Therefore, the main aim of this work is to assess
the in vitro expression of potential virulence factors of
C. bracarensis strains and to determine the effect of
amphotericin B and fluconazole against planktonic
cells and on the formation and control of biofilms.
Materials and Methods
Organisms
Three C. bracarensis isolates were used in this study:
(i) NCYC 3133, isolated from a central venous
catheter in the United Kingdom; (ii) CNM-CL-7030,
isolated from a catheter exudate and belonging to the
Spanish National Centre for Microbiology Yeast
Collection; and (iii) 153 MT, obtained from a vaginal
sample of a patient with candidiasis, at the Hospital of
Sa˜o Marcos (Braga, Portugal). These strains were
identified by sequencing of the D1/D2 domain of the
26S rDNA and ITS1/ITS2 regions [7]. Additionally,
two reference strains of C. albicans (ATCC 90028)—
the Candida species more studied at all levels—and C.
glabrata (ATCC 2001)—the species that presents
more phenotypic similarities with C. bracarensis—
from the American Type Culture Collection (ATCC),
were also used [5, 7].
Biofilm Formation and Extracellular Matrix
Composition
Strains were subcultured on yeast peptone dextrose
(YPD) agar medium, which was composed by 1 % (w/
v) yeast extract, 2 % (w/v) peptone, 2 % (w/v) glucose
and 2 % (w/v) agar, for 24 h at 37 C. Then, yeasts
were cultured on YPD broth for 18 h at 37 C under
agitation at 120 rpm. After incubation, cells were
harvested and washed twice (with phosphate-buffered
saline [PBS; pH 7.5, 0.1 M]) by centrifugation (at
3000g for 10 min at 4 C). Afterward, cells were
enumerated using a Neubauer counting chamber and
adjusted to a concentration of 1.0 9 107 cells/ml in
RPMI 1640 (Sigma, Saint Louis, Missouri, USA)
media. Then, biofilms were formed in 96-well poly-
styrene microtiter plates (Orange Scientific, Braine-l’
Alleud, Belgium). A volume of 200 ll of the standard-
ized cell suspensions (1.0 9 107 cells/ml in RPMI
1640) was added to each well. The plates were
incubated at 37 C in an orbital shaker at 120 rpm for
24 h. At the end of the respective time, the mediumwas
removed and all wells were washed once with PBS (pH
7.5, 0.1 M) to remove the non-adherent cells.
Biofilms were firstly analyzed in terms of the
number of colony forming units (CFUs). For that,
200 ll of PBS was added to each well and then
biofilms were removed from the surface by scrapping
[13]. Complete removal of the biofilm was confirmed
by subsequent crystal violet (CV) staining [14]. The
biofilm suspensions were then vortexed for 5 min (to
disrupt the biofilm matrix), and later, serial decimal
dilutions (in PBS) were plated onto YPD agar and
incubated for 24 h at 37 C. The results were then
expressed as the number of CFUs (Log10 CFUs).
Biofilms were also analyzed in terms of total
biomass quantification by CV staining [14]. For that,
after washing it, 200 ll of methanol (100 % v/v) were
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added to each well, to fix the cells. Methanol was
removed after 15 min of contact and the microtiter
plates dried at room temperature. Afterward, 200 ll of
CV (1 % v/v) were added to each well, which
remained in contact with the cells for 5 min. Then,
CV was aspirated, the wells were washed twice with
ultra-pure water and 200 ll of acetic acid (33 % v/v)
were added to dissolve the stain. Lastly, absorbance of
CV solutions was read in a microtiter plate reader
(Bio-Tek Synergy HT, Izasa, Lisbon, Portugal) at
570 nm (Abs570 nm).
In order to analyze the composition of the extra-
cellular biofilm matrix (ECM) which requires the
production of higher amounts of biofilms, 24-well
polystyrene microtiter plates (Orange Scientific,
Braine-l’ Alleud, Belgium) were used, in which 1 ml
of standardized yeast suspensions (1.0 9 107 cells/ml
in RPMI 1640) were placed. Microtiter plates were
incubated for 24 h at 37 C and 120 rpm. After
biofilm formation, the culture medium was removed,
wells were washed once with PBS (pH 7.5, 0.1 M) and
cells were scraped from wells. The biofilms were then
resuspended in PBS to a final volume of 5 ml. To
determine the dry weight of each sample, 1 ml of the
suspension was vortexed for 30 s, filtered through a
0.45 lm nitrocellulose filter and left to dry at 80 C
for 24 h. The remaining 4 ml of suspensions was
sonicated (Ultrasonic Processor, Cole-Parmer, Illi-
nois, USA), for 30 s at 30 W, and centrifuged at
5000 rpm for 5 min at 4 C, in order to recover the
matrix. The supernatant was filtered (through a
0.45 lm filter) and stored at -20 C until they were
used to protein and carbohydrate quantification. The
content of protein present in the extracellular biofilm
matrix was determined by the BCAKit (Bicinchoninic
Acid, Sigma-Aldrich, St Louis, USA), using Bovine
Serum Albumin (BSA) as standard. The total carbo-
hydrates present in the biofilmmatrix were determined
according to the procedure described by Dubois et al.
[15], using glucose as standard. The carbohydrate and
protein contents were normalized by biofilm dry
weight. These assays were performed at least three
times for each strain and medium.
Enzymatic Activity
In order to determine the protease activity, fresh
cultured colonies were placed onto protease agar
medium containing 2 % (w/v) agar, 1.2 % (w/v) yeast
carbon base, 0.01 % (w/v) yeast extract and 0.2 % (w/
v) BSA with pH 5.0, according to Ru¨chel et al. [16].
Afterward, the plates were incubated at 37 C for
4 days. After incubation, each plate of protease agar
medium was placed in contact with 15 ml of dye
solution (0.1 % (w/v) amido black, 30 % (v/v)
methanol, 10 % (v/v) acetic acid and 60 % ultra-pure
water) for 1 h. Then the plates were washed twice with
acetic acid (33 % v/v) and dried at room temperature.
Phospholipase activity was determined according to
Price et al. [17]. For that, colonies were cultured onto
phospholipase agar medium composed by 2 % (w/v)
agar, 1 % (w/v) peptone, 2 % (w/v) glucose, 1 M
NaCl, 5 mM CaCl2 and 8 % (w/v) egg yolk, followed
by incubation at 37 C for a period of 3 days.
The determination of the enzymatic activity was
performed by observation of the presence or absence
of an opaque inhibition halo around the colonies in
both agar media. The enzymatic activity was assessed
by the ratio between the colony diameter and the halo
plus the colony diameter—Pz value—according to
Price et al. [17]. These assays were performed in
triplicate, and C. tropicalis ATCC 750 was used as a
positive control and C. glabrata ATCC 2001 as a
negative control, in the proteolytic activity analysis
[18]. Candida albicans ATCC 90028 was used as a
positive control and C. glabrata ATCC 2001 as a
negative control concerning phospholipase activity
determination [19].
Hemolytic activity was evaluated using a modifica-
tion of the plate assay described by Luo et al. [20]. Fresh
cultured colonies were placed inside of sugar-enriched
sheep blood medium, with 2 % (w/v) peptone, 1 % (w/
v) agar, 7 % fresh sheep blood, 3 % (w/v) glucose. The
plates were incubated at 37 C for 3 days, and later the
hemolytic activity was classified as absent (without
halo), partial or total (transparent halo). This experi-
ment was performed in triplicate and C. tropicalis
ATCC 750 used as a positive control [18].
Planktonic Cells Antifungal Susceptibility Tests
The reference method described by the Clinical and
Laboratory Standards Institute (CLSI) for broth dilu-
tion antifungal susceptibility testing of yeast (M27-
A2) was used to determine the minimum inhibitory
concentration (MIC).
Mycopathologia (2015) 180:305–315 307
123
As described in the CLSI M27-A2 standard, MICs
were interpreted as follows: (i) amphotericin B:
MIC[ 1 lg/ml—it is probably resistant (R); (ii)
fluconazole: MIC B 8 lg/ml—susceptible (S);
16\MIC\ 32 lg/ml—susceptible-dose-dependent
(SDD) and MIC C 64 lg/ml—resistant (R). These
were repeated in at least three independent assays,
being individual samples analyzed in triplicate.
Antifungal Agents Effect on Formation and Pre-
formed Biofilms
In order to assess the effect of antifungal agents on
biofilm formation and pre-formed biofilms, flucona-
zole (at 50, 312.5 and 625 lg/ml) and amphotericin B
(at 0.5, 1 and 2 lg/ml) prepared in RPMI medium
were added at the beginning of the biofilm formation
and after 24 h of growth (pre-formed biofilms).
Then, in the first approach, 96-well polystyrene
plates (Orange Scientific) were used and each well was
filled with 100 ll of antifungal and 100 ll of the
standardized cell suspensions (2.0 9 107 cells/ml in
RPMI 1640). The plates were incubated at 37 C and
120 rpm for 24 h. In relation to the pre-formed
biofilms, 100 ll of RPMI 1640 medium and 100 ll
of the cell suspensions were added to the selected
wells, which were incubated at 37 C in an shaker (at
120 rpm). After 24 h, 200 ll of culture medium was
removed and an equal volume of the respective
antifungal concentration was added to the plates that
were incubated for further 24 h. After each incubation
time, the culture medium was aspirated and the wells
were washed once with PBS (pH 7.5, 0.1 M). The
results were assessed using CFUs enumeration and by
the total biomass quantification (through CV staining).
The results were presented as absorbance values
(Abs570 nm) and Log10 CFUs. Experiments were
performed in triplicate and in four independent assays.
Statistical Analysis of Data
Statistical analysis was performed using GraphPad
Software (San Diego, CA, USA). The two-way
ANOVA with the Bonferroni post hoc test was used
to determine statistical differences between the several
strains studied. The same procedure was also used to
compare the controls (0 lg/ml) with the resistance of
strains to different concentrations of antifungal agent.
All tests were performedwith a 95 % confidence level.
Results
Candida bracarensis Strains are Able to form
Biofilm
Biofilm formation ability by C. bracarensis was
performed in RPMI 1640 during 24 h and quantified
by CFUs enumeration (Fig. 1a) and total biomass
determination (Fig. 1b). It was evident that all C.
bracarensis strains were able to form biofilm, but with
some specific differences concerning the strains. In
terms of the number of viable cells (Fig. 1a), no
statistical differences were observed among the three
C. bracarensis strains’ biofilms (p[ 0.05), even
comparatively to C. albicans and C. glabrata strains
(p[ 0.05). Contrarily, concerning the total biomass
quantification, significant differences were detected
between the C. bracarensis strains (p\ 0.05), with C.
bracarensis 153 MT presenting the highest value
followed by the strains CNM-CL-7030 and NCYC
3133.
In order to better characterize C. bracarensis
biofilms, protein and carbohydrates content,
extracted from biofilm matrices, was also assessed
(Table 1). The results showed that likewise, in C.
albicans and C. glabrata species, proteins and
carbohydrates are matrices constituents of the C.
bracarensis biofilm. Concerning the protein content,
results showed no statistically significant differences
(p[ 0.05) between the protein levels extracted from
matrices of the different strains, even comparatively
to C. albicans and C. glabratamatrices (p[ 0.05). In
relation to the carbohydrate quantification, no statis-
tical differences were found between the C.
bracarensis strains tested (p[ 0.05); however, it
was verified that biofilmmatrix of the C. glabrata had
significantly higher quantity of carbohydrate than the
other biofilm matrices (p\ 0.001 vs. C. albicans and
C. bracarensis).
Candida bracarensis Present Proteolytic
and Hemolytic Activity
Enzymes’ production is described as an important
Candida virulent factor; thus, the proteolytic, phos-
pholipidic and hemolytic activities of C. bracarensis
strains were accessed. After incubation of fresh C.
bracarensis colonies onto agar medium supplemented
with BSA, it was possible to conclude that from the
308 Mycopathologia (2015) 180:305–315
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three strains used, only C. bracarensis (NCYC 3133)
presented proteolytic activity (Pz = 0.44), likewise C.
tropicalis (Pz = 0.44) and C. albicans (Pz = 0.47).
Moreover, C. bracarensis strains were not able to
produce phospholipases (Pz = 1.00), like C. glabrata
(Pz = 1.00) and in opposition to C. albicans
(Pz = 0.38). Nevertheless, all C. bracarensis strains
tested were able to express total hemolytic activity on
sugar-enriched sheep blood medium.
Candida bracarensis Planktonic Cells Response
to Antifungal Agents is Variable
The levels of Candida strains susceptibility to ampho-
tericin B and fluconazole, in the planktonic lifestyle,
are presented in Table 2.
Concerning amphotericin B, it was verified that, in
opposition to all other strains, C. bracarensis NCYC
3133 presented a more resistant profile (MIC[ 1 lg/
ml). In the case of fluconazole, it was possible to infer
that all C. bracarensis strains are susceptible-dose-
dependent, in opposition to C. albicans ATCC 90028
and C. glabrata ATCC 2001, which are resistant to
this agent.
Candida bracarensis Biofilm Formation is
Reduced by Antifungal Agents
To infer about the effect of amphotericin B and
fluconazole in C. bracarensis biofilm formation,
biofilms were formed in the absence and presence
of both antifungal agents. The results, presented as
(a) (b)
Fig. 1 Candida bracarensis biofilm formation. (a) Number of
viable cells (Log10 CFUs) and (b) absorbance values (Abs570nm)
of crystal violet solutions of biofilm formed in RPMI during
24 h by Candida species. Error bars represent standard
deviation, as result of three assays performed for each strain
and medium. *Statistical difference compared to biofilms
formed by other strains of the C. bracarensis species (p\ 0.05)
Table 1 Protein and carbohydrate contents (mg/g of biofilm dry weight) extracted from biofilms matrices formed in RPMI during
24 h by different Candida strains. The values are means ± standard deviations
Species Biofilm matrix composition (mg/g of biofilm dry weight)
Proteins Carbohydrates
C. bracarensis NCYC 3133 5.08 ± 0.29 58.07 ± 32.82
C. bracarensis CNM-CL-7030 12.98 ± 6.46 34.47 ± 10.34
C. bracarensis 153 MT 1.70 ± 1.10 45.17 ± 21.98
C. glabrata ATCC 2001 7.57 ± 1.25 157.38 ± 40.48***
C. albicans ATCC 90028 10.22 ± 1.96 38.15 ± 15.96
Statistical difference compared to biofilm matrix formed by other Candida species (*** p\ 0.001)
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the number of viable cells (Fig. 2a, b) and the total
biomass values (Fig. 2c, d), highlight the incapac-
ity of the fungicide (amphotericin B) and fungi-
static (fluconazole) agents to totally inhibit biofilm
formation, within the range of concentrations
tested.
Regarding amphotericin B, all tested concentra-
tions caused some reduction (p\ 0.05) in the
Table 2 In vitro
susceptibility of Candida
strains for amphotericin B
and fluconazole
R resistant, S susceptible;
SDD susceptible-dose-
dependent
Species Susceptibility category (MIC lg/ml)
Amphotericin B Fluconazole
C. bracarensis NCYC 3133 S ([1) SDD (16–32)
C. bracarensis CNM-CL-7030 S (0.5–1) SDD (16–32)
C. bracarensis 153 MT S (0.25–0.5) SDD (16–32)
C. glabrata ATCC 2001 S (0.5–1) R (C64)
C. albicans ATCC 90028 S (0.5–1) R (C64)
(a)
(b)
(c)
(d)
Fig. 2 Amphotericin B and fluconazole effect against biofilm
formation of C. bracarensis. (a, b) Number of viable cells
(Log10 CFUs) of Candida species and (c, d) absorbance values
(Abs570nm) of CV solutions of biofilm formed in the presence of
(a, c) amphotericin B and (b, d) fluconazole. Error bars
represent standard deviation, as result of four independent
assays, where each condition was analyzed in triplicate.
Statistical difference compared to respective control
(*p\ 0.05; **p\ 0.01; ***p\ 0.001)
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number of viable cells (Fig. 2a) and biofilm biomass
(Fig. 2c). It is important to address that this effect
increased with the amount of antifungal tested. In
addition, it was also verified that C. glabrata and C.
bracarensis 153 MT biofilms presented the highest
reduction in terms of the number of viable cells and
biofilm biomass. On the other hand, C. bracarensis
NCYC 3133 biofilm had the lowest reduction in the
biomass.
In what concerns fluconazole (Fig. 2b, d), it can be
seen that this antifungal agent significantly inhibited
the biofilm formation of all species (p\ 0.05), but
with lower extension in the case of C. glabrata. In
Fig. 2b it is possible to observe that fluconazole
affected biofilm formation in a similar way for the
three C. bracarensis strains. During C. bracarensis
biofilms’ formation, the inhibition imposed by differ-
ent fluconazole concentrations in the viable cells’
number was higher than inC. glabrata andC. albicans
biofilms. Contrarily, and according to values from
Fig. 2d, the total biomass reduction in the C.
bracarensis biofilm was lower than in the C. albicans
biofilm, but remained higher than in the C. glabrata
biofilms. In addition, among C. bracarensis species,
the lowest biomass reduction happened in the biofilm
of strain 153 MT (\28.5 %), regardless of the tested
fluconazole concentration.
Pre-formed Biofilms of Candida bracarensis are
Low Affected by Antifungal Agents
To evaluate the effect of amphotericin B and flucona-
zole on pre-formed biofilms of C. bracarensis, 24 pre-
formed biofilms were treated with amphotericin B and
fluconazole and its effect was evaluated after addi-
tional 24 h (Fig. 3). The number of viable cells
(Fig. 3a, b) and the total biomass values (Fig. 3c, d)
obtained showed that the antifungal agents’ effect was
effectively lower comparatively to the effect observed
during biofilm formation (Fig. 2), however, with some
specific differences concerning the strains and anti-
fungal agent test.
In relation to amphotericin B, all concentrations
tested were unable to reduce pre-formedC. bracarensis
NCYC 3133 biofilm (p[ 0.05), either in terms of the
number of viable cells (Fig. 3a) or in terms of total
biomass (Fig. 3c). In relation to the other strains, it was
verified that 0.5 lg/ml of amphotericin B had a
statistically significant positive effect in the reduction
in the number of viable cells of C. bracarensis 153 MT
(p\ 0.001) and C. albicans ATCC 90028 (p\ 0.01).
However, the total biomass values revealed only a
significantly positive effect (p\ 0.01) in the biofilm of
these species for values of concentrations higher than
1 lg/ml. Moreover, in the case of C. glabrata and C.
bracarensis CNM-CL-7030 biofilms, a significant
reduction (p\ 0.05) in the number of viable cells
was observed, despite only for concentrations of 1 and
2 lg/ml, whereas the biomass of these biofilms suffered
a statistically significant decrease with 0.5 lg/ml
(p\ 0.05) and 2 lg/ml (p\ 0.001), respectively.
In the case of fluconazole, this antifungal agent had
no effect on the number of viable C. bracarensis
NCYC 3133 biofilm’s cells (p[ 0.05), comparatively
to control (Fig. 3b). Nevertheless, in Fig. 3d, it is
possible to observe that the total biomass increased
significantly in the presence of 625 lg/ml of flucona-
zole comparatively to the control (p\ 0.01). The
same happened for C. glabrata biofilm, regarding the
biomass values. Figure 3b also shows that the number
of viable cells of C. albicans and C. bracarensis 153
MT biofilms statistically decreased, however, only for
higher concentrations of fluconazole (625 lg/ml). In
contrast, and concerning total biomass values
(Fig. 3d), it was observed that both strains presented
opposite behaviors in relation to the fluconazole
action. Furthermore, fluconazole, at the same concen-
tration (50 lg/ml), was able to reduce the number of
C. bracarensis CNM-CL-7030 biofilms (p\ 0.01)
and its total biomass amount (p\ 0.05) comparatively
to the control.
Discussion
Candida bracarensis is a commensal human fungus
and, comparatively to C. albicans and to other
Candida species, relatively few investigations have
been carried out to assess its virulence factors and its
susceptibility to traditional antifungal agents [6, 7].
Moreover, initially, C. bracarensis was misclassified
as C. glabrata upon its discovery, and the results
presented here highlight these differences, not only
concerning species but even strains [4, 7].
Biofilm formation is an important phenomena that
contributes for the survival and colonization of
Candida species in host tissues and medical devices
[21]. In the present study, it was observed for the first
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time that C. bracarensis strains were able to form
biofilms, although in different extents depending on
the strains (Fig. 1), likewise other Candida species
(such as C. albicans and C. glabrata) [21].
One of the most important characteristics of fungal
biofilms is the presence and the composition of the
ECM [8, 22]. Biofilm matrix is composed by several
products secreted by microbial cells and acts as a
barrier to the diffusion of antimicrobial agents,
preventing, for that reason, the penetration and the
access of drugs to cells located at the base of the
biofilm [8, 23]. This study highlights, for the first time,
that C. bracarensis biofilm matrices are constituted by
proteins and carbohydrates, likewise C. albicans and
C. glabrata biofilms (Table 1). Nevertheless, signif-
icant differences were also observed concerning the
strains, specifically in terms of carbohydrates quanti-
ties. In fact, C. glabrata presented the highest values
of carbohydrates comparatively to other strains under
study. These results are in concordance with those
revealed by several authors [8, 21], who showed that
ECM of C. albicans biofilm contains a high level of
carbohydrates and a low level of proteins and that
biofilm matrices of C. glabrata are composed by high
quantities of carbohydrates and proteins.
Among the several virulence factors, the ability to
secrete hydrolytic enzymes has already been described
for several Candida species, but not for C. bracarensis
[18, 24–26]. Those compounds play a major role in the
pathogenicity of these microorganisms since they are
responsible for host tissue destruction [5]. The present
work revealed that at least one strain of C. bracarensis
(a) (c)
(b) (d)
Fig. 3 Amphotericin B and fluconazole effect against C.
bracarensis 24 h pre-formed biofilm. a, b Number of viable
cells (Log10 CFUs) of Candida species and c, d absorbance
values (Abs570nm) of CV solutions of biofilm treated with (a,
c) amphotericin B and (b, d) fluconazole. Error bars represent
standard deviation, as result of four independent assays, where
each condition was analyzed in triplicate. Statistical difference
compared to respective control (*p\ 0.05; **p\ 0.01;
***p\ 0.001)
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(NCYC 3133) was able to secrete proteases, like C.
tropicalis and C. albicans. Negri et al. [24] demon-
strated proteolytic activity in some C. tropicalis
clinical isolates from hospitalized patients, and Kumar
et al. [25] detected that 83.6 % of C. albicans isolates
obtained from immunocompromised patients were
capable to produce proteases. Moreover, concerning
phospholipase activity, none of the strains of C.
bracarensis produced extracellular phospholipases,
like C. glabrata, but unlike C. albicans. On the
contrary, all strains of C. bracarensis expressed total
hemolytic activity, like the other species [18, 24, 26].
Concerning the antifungal agents’ effect, C.
bracarensis strains presented different susceptibility
to amphotericin B and fluconazole, in planktonic
lifestyle (Table 2). The present work showed that all
C. bracarensis strains presented different MICs values
for amphotericin B, with C. bracarensis NCYC 3133
being the most resistant strain even comparatively to
C. albicans and C. glabrata. The results obtained for
C. bracarensis 153MT are similar to those reported by
Bishop et al. [27]. Unlike to what was observed for
amphotericin B, the planktonic cells of the three C.
bracarensis strains showed a similar behavior in the
presence of fluconazole (Table 2). All strains could be
classified as susceptible-dose-dependent, which
allows the confirmation that these strains had not yet
developed intrinsic resistance to this azole. Further-
more, in a previous study developed by Bishop et al.
[27], C. bracarensis 153 MT (also designated as C.
bracarensis TS) presented a fluconazole MIC value of
8 lg/ml, slightly lower than the one obtained in this
work. Moreover, the planktonic cells ofC. bracarensis
presented higher susceptible to fluconazole than the C.
albicans andC. glabrata strains assayed. In opposition
to what was expected, the susceptibility presented by
C. bracarensis contrasted with the well-known resis-
tance of C. glabrata to fluconazole [28, 29].
As it is known, Candida biofilms are generally
10–1000 times more resistant to antifungal agents than
planktonic cells [22]. Nevertheless, in relation to C.
bracarensis biofilms, there is still no investigation and,
subsequently, there is a lack of information about the
effect of amphotericin B and fluconazole against
biofilm formation. Thus, after checking that C.
bracarensis strains were able to form biofilms, the
effect of amphotericin B and fluconazole on biofilm
formation and pre-formed biofilms was assessed
(Figs. 2, 3). Likewise to what was described for all
Candida species biofilms, C. bracarensis biofilm
(Figs. 2, 3) presented also higher resistance compar-
atively to its planktonic counterparts (Table 2). In
addition, it was verified that the antifungal effect was
lower in the pre-formed biofilms (Fig. 3) than during
biofilm formation (Fig. 2), regardless the agent tested.
In fact, as it has been described, the antifungal
resistance of Candida species biofilms increases with
the complexity of biofilm structure [30]. The devel-
opment of complex architectures restricts the penetra-
tion of drugs through the ECM, also hampering the
access of these agents to cells present in the deep
layers of the biofilm [22, 31]. During C. bracarensis
biofilms’ formation in the presence of amphotericin B
(Fig. 2a, c), the biofilm of strain NCYC 3133
presented the lowest susceptibility, while the C.
bracarensis 153MT biofilms was the most susceptible.
These observations are in agreement with the results
obtained for C. bracarensis planktonic cells suscep-
tibility to amphotericin B (Table 2). Moreover, the
biofilm of the C. bracarensis strains presented a
similar susceptibility to C. glabrata, concerning
amphotericin B. Candida bracarensis was also more
susceptible than C. albicans strain accessed under this
work. Fluconazole was also able to interfere in the
biofilm formation of all C. bracarensis strains
(Fig. 2b, d). Furthermore, the effect of this azole
against C. bracarensis biofilm formation was higher
than the observed for biofilms of C. glabrata and C.
albicans. These findings are in accordance with what
was observed for susceptibility of the planktonic cells
to fluconazole (Table 2).
In the pre-formed biofilms (Fig. 3b, d), the strains
NCYC 3133 and 153 MT presented less susceptibility
to fluconazole, among the C. bracarensis strains.
Comparatively to other Candida species, the biofilm
of C. bracarensis CNM-CL-7030 and C. albicans was
the most susceptible to fluconazole in terms of the
number of viable cells and values of total biomass,
respectively. In the other hand, fluconazole presented
the lower effect against pre-formed biofilms of C.
bracarensis NCYC 3133 and C. glabrata, with a
significant increase in the total biomass values, when
in the presence of 625 lg/ml. This observation
contradicts the high susceptibility demonstrated by
planktonic cells of C. bracarensis NCYC 3133 to
fluconazole (Table 2).
The increase in total biomass values, observed in
the biofilms of C. bracarensis NCYC 3133 and C.
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glabrata, clearly indicates the presence of biofilm
resistance mechanisms to fluconazole. Although these
mechanisms are not fully understood, there is a
consensus in relation to some of them, specifically in
the case of C. albicans biofilm [5]. One of them is the
overexpression of drug target [32] and the presence of
persister cells [33]. Another important factor involved
in the antifungal resistance of biofilms is the physi-
ological stress. This stress causes mutations in proteins
that interfere in biofilm formation and, consequently,
in its resistance [32]. ECM has been referred as an
important mechanism also in the biofilm antifungal
resistance because it functions as a protective barrier
for the cells embedded in it, by hampering the
diffusion of antifungal agents [32]. Nevertheless, and
through the results obtained for ECM composition of
strains under study (Table 1), no correlation was
found between the matrix composition and the biofilm
antifungal resistance, with exception of C. glabrata.
In conclusion, this study highlighted the differences
between the C. bracarensis strains and the C. glabrata
(or C. albicans), in terms of some virulence attributes
and antifungal resistance. Specifically it was demon-
strated, for the first time, that C. bracarensis strains
tested are able to form biofilms, which are constituted
by proteins and carbohydrates in their ECM. More-
over, it is important to highlight that C. bracarensis
strains have proteinase and hemolytic activity and are
unable to produce phospholipase and filamentous
forms. Moreover, although the majority of the plank-
tonic strains presented susceptibility to both ampho-
tericin B and fluconazole, their biofilms appear much
more resistant to these antifungals, similarly to other
Candida species.
Despite being a rare species, due to the propensity
of the isolates of C. bracarensis to display antifungal
resistance and virulence attributes, the monitorization
of these emerging pathogens is recommended. Con-
cerning its identification, the use of standard chemo-
taxonomic methods by PCR fingerprinting with primer
T3B [7] coupled with single or multiplex PCR are
suggested [34].
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